Clinical Trials
42 trialsLosartan and Paclitaxel in Platinum Resistant Ovarian Cancer
Massachusetts General Hospital
A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Bristol-Myers Squibb
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
CRS/HIPEC
Mercy Medical Center
Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).
University of Miami
Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer
Canadian Cancer Trials Group
Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients
University of Kansas Medical Center
Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
University of Virginia
Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma
Sotio Biotech Inc.
Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer
Saitama Medical University International Medical Center
CHIMOVIP
Groupe Hospitalier Diaconesses Croix Saint-Simon
Neoadjuvant Therapy for Ovarian Cancer
Columbia University
CLIO
Universitaire Ziekenhuizen KU Leuven
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
University of Maryland, Baltimore
A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer
University of Iowa
Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Masonic Cancer Center, University of Minnesota
Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma
Gynecologic Oncology Associates
Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer
University of California, Irvine
Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma
Sotio Biotech Inc.
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
Merrimack Pharmaceuticals
S0009
SWOG Cancer Research Network
Combination Chemotherapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer
AGO Study Group
Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma
National Cancer Institute (NCI)
p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
Shenzhen SiBiono GeneTech Co.,Ltd
Combination Chemotherapy in Treating Patients With Platinum-Resistant Recurrent Ovarian Cancer
University of Southern California
Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Sequential Chemotherapy in Treating Patients With Residual Disease Following Surgery for Stage IIB, Stage III, or Stage IV Ovarian Cancer
National Cancer Institute (NCI)
Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Paclitaxel and Cisplatin as First-Line Treatment for Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Cancer
National Cancer Institute (NCI)
Paclitaxel and Celecoxib in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer
GOG Foundation
Paclitaxel in Treating Patients With Recurrent or Progressive Advanced Ovarian Cancer
Memorial Sloan Kettering Cancer Center
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Fox Chase Cancer Center
Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
GOG Foundation
Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer
GOG Foundation
Paclitaxel in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer
GOG Foundation
S9912 Combination Chemo in Stage III Ovarian Cancer,
SWOG Cancer Research Network
Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer
NYU Langone Health
Combination Chemotherapy in Treating Patients With Metastatic Ovarian Cancer or Non-small Cell Lung Cancer
University of California, San Francisco
Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors
GlaxoSmithKline
Weekly Infusions of Paclitaxel in Treating Women With Stage III or Stage IV Ovarian Cancer Refractory to Paclitaxel and Platinum
National Cancer Institute (NCI)
Treatment of Paclitaxel Plus Carboplatin Followed by Gemcitabine Plus Carboplatin for Patients With Epithelial Ovarian Cancer
Eli Lilly and Company